J&J’s $16.6B purchase of Abiomed is the reason people are starting to follow Triphasic’s journey.
The recent acquisition bodes well for the future of Triphasic, a Perth based medtech development company.
Their patented, reciprocating cardiac pump, designed to be used in heart surgery as part of what is commonly known as the heart lung machine, is lovingly called the ‘Pulse of Life’ by the team.
The perfusion system and device generate a pulsatile flow of blood into the circulation before it re-enters the body during cardiac surgery.
Many of you may not realise that the pressure the pulse creates in the arteries pushes the blood to the capillaries, taking oxygen and nutrients to the capillaries. The veins then return the blood to the heart, removing toxins and waste from cells.
In technical terms, Triphasic has developed a novel positive displacement cardiac pump that is able to mimic a patient specific physiological blood flow and provide optimum microcirculation to improve patient outcome in cardiac surgery.
The technology uses an ECG signal, the pump synchronises with the cardiovascular autoregulation system, which controls contraction and dilation of blood vessels to optimise efficiency in blood flow.
Leading the way, the Trilab Pump (the forerunner to the TriClinical) is already being tested in labs in Germany and the Netherlands and will soon be trialled in one of the newest medical university departments in Australia.